Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multi-center, Open-Label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of PRLX 93936 Administered Intravenously Daily for Five Days Followed by a 23-Day Rest Period in Patients With Advanced Solid Tumors

NCT00528047 is registered in ClinicalTrials.gov with Prolexys Pharmaceuticals as lead sponsor.

NCT NCT00528047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00528047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multi-center, Open-Label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of PRLX 93936 Administered Intravenously Daily for Five Days Followed by a 23-Day Rest Period in Patients With Advanced Solid Tumors
Lead sponsor
Prolexys Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2007
Completion date
November 30, 2011
Enrollment
37 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer